Enhancement of TRAIL-Mediated Apoptosis by Genistein in Human Hepatocellular Carcinoma Hep3B Cells: Roles of p38 MAPK Signaling Pathway |
Jin, Cheng-Yun
(Department of Biomaterial Control (BK21 program) and Blue-Bio Industry Regional Innovation Center, Dongeui University)
Park, Cheol (Medical Research Institute, Chungbuk National University College of Medicine) Park, Sang-Eun (Department of Internal Oriental Medicine, Dongeui University College of Oriental Medicine) Hong, Sang-Hoon (Department of Internal Oriental Medicine, Dongeui University College of Oriental Medicine) Choi, Yung-Hyun (Department of Biomaterial Control (BK21 program) and Blue-Bio Industry Regional Innovation Center, Dongeui University) |
1 | Jin, C. Y., C. Park, J. Cheong, B. T. Choi, T. H. Lee, J. D. Lee, W. H. Lee, G. Y. Kim, C. H. Ryu, and Y. H. Choi. 2007. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett 257, 56-64. DOI ScienceOn |
2 | Jin, C. Y., C. Park, G. Y. Kim, S. J. Lee, W. J. Kim, and Y. H. Choi. 2009. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem. Biol. Interact. 180, 143-150. DOI ScienceOn |
3 | Jin, C. Y., C. Park, S. K. Moon, G. Y. Kim, T. K. Kwon, S. J. Lee, W. J. Kim, and Y. H. Choi. 2009. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs 20, 713-722. DOI ScienceOn |
4 | Kang, J. L., H. W. Lee, H. J. Kim, H. S. Lee, V. Castranova, C. M. Lim, and Y. Koh. 2005. Inhibition of SRC tyrosine kinases suppresses activation of nuclear factor-B, and serine and tyrosine phosphorylation of in lipopolysaccharide- stimulated raw 264.7 macrophages. J. Toxicol. Environ. Health 68, 1643-1662. DOI ScienceOn |
5 | Kim, H., E. H. Kim, Y. W. Eom, W. H. Kim, T. K. Kwon, S. J. Lee, and K. S. Choi. 2006. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res. 66, 1740-1750. DOI ScienceOn |
6 | Abdollahi, T. 2004. Potential for TRAIL as a therapeutic agent in ovarian cancer. Vitam. Horm. 67, 347-364. DOI |
7 | Abdollahi, T., N. M. Robertson, A. Abdollahi, and G. Litwack. 2005. Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells. Apoptosis 10, 1383-1393. DOI ScienceOn |
8 | Van Geelen, C. M., E. G. de Vries, and S. de Jong. 2004. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7, 345-358. DOI ScienceOn |
9 | Wang, C., T. Chen, N. Zhang, M. Yang, B. Li, X. Lu, X. Cao, and C. Ling. 2009. Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1- JNK/p38 and inhibiting kinase-NFB. J. Biol. Chem. 284, 3804-3813. DOI |
10 | Weldon, C. B., A. P. Parker, D. Patten, S. Elliott, Y. Tang, D. E. Frigo, C. M. Dugan, E. L. Coakley, N. N. Butler, J. L. Clayton, J. Alam, T. J. Curiel, B. S. Beckman, B. M. Jaffe, and M. E. Burow. 2004. Sensitization of apoptotically- resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int. J. Oncol. 24, 1473-1480. |
11 | Yamanaka, T., K. Shiraki, K. Sugimoto, T. Ito, K. Fujikawa, M. Ito, K. Takase, M. Moriyama, T. Nakano, and A. Suzuki. 2000. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32, 482-490. DOI ScienceOn |
12 | Pei, Z., L. Chu, W. Zou, Z. Zhang, S. Qiu, R. Qi, J. Gu, C. Qian, and X. Liu. 2004. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39, 1371-1381. DOI ScienceOn |
13 | Zauli, G., E. Rimondi, V. Nicolin, E. Melloni, C. Celeghini, and P. Secchiero. 2004. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104, 2044-2050. DOI ScienceOn |
14 | Lub-de Hooge, M. N., S. de Jong, C. Vermot-Desroches, J. E. Tulleken, E. G. de Vries, and J. G. Zijlstra. 2004. Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis- inducing ligand level mediated by the p38 mitogen- activated protein kinase signaling pathway. Shock 22, 186-188. DOI ScienceOn |
15 | Park, J. H., E. J. Oh, Y. H. Choi, C. D. Kang, H. S. Kang, D. K. Kim, K. I. Kang, and M. A. Yoo. 2001. Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells. Int. J. Oncol. 18, 997-1002. |
16 | Pinski, J., Q. Wang, M. L. Quek, A. Cole, J. Cooc, K. Danenberg, and P. V. Danenberg. 2006. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 66, 1136-1143. DOI ScienceOn |
17 | Raffoul, J. J., Y. Wang, O. Kucuk, J. D. Forman, F. H. Sarkar, and G. G. Hillman. 2006. Genistein inhibits radiation-induced activation of NF-B in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6, 107. DOI |
18 | Shankar, S, and R. Srivastava. 2004. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7, 139-156. DOI ScienceOn |
19 | Ravindranath, M. H., S. Muthugounder, N. Presser, and S. Viswanathan. 2004. Anticancer therapeutic potential of soy isoflavone, genistein. Adv. Exp. Med. Biol. 546, 121-165. DOI |
20 | Sarkar, F. H., S. Adsule, S. Padhye, S. Kulkarni, and Y. Li. 2006. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev. Med. Chem. 6, 401-407. DOI ScienceOn |
21 | Srivastava, R. K. 2001. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3, 535-546. DOI ScienceOn |
22 | Kim, S. H., S. H. Kim, S. C. Lee, and Y. S. Song. 2009. Involvement of both extrinsic and intrinsic apoptotic pathways in apoptosis induced by genistein in human cervical cancer cells. Ann. N Y Acad. Sci. 1171, 196-201. DOI ScienceOn |
23 | Kim, Y. H., J. W. Park, J. Y. Lee, and T. K. Kwon. 2004. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25, 1813-1820. DOI |
24 | Kim, Y. S., R. F. Schwabe, T. Qian, J. J. Lemasters, and D. A. Brenner. 2002. TRAIL-mediated apoptosis requires NF- B inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36, 1498-1508. |
25 | Kischkel, F. C., D. A. Lawrence, A. Chuntharapai, P. Schow, K. J. Kim, and A. Ashkenazi. 2000. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-620. DOI ScienceOn |
26 | Lee, M. W., J. H. Bach, H. J. Lee, D. Y. Lee, W. S. Joo, Y. S. Kim, S. C. Park, K. Y. Kim, W. B. Lee, and S. S. Kim. 2005. The activation of ERK1/2 via a tyrosine kinase pathway attenuates trail-induced apoptosis in HeLa cells. Cancer Invest 23, 586-592. DOI ScienceOn |
27 | Lamy, V., S. Bousserouel, F. Gosse, C. Minker, A. Lobstein, and F. Raul. 2011. Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancer-derived metastatic cells. Oncol. Rep. 26, 109-114. |
28 | LeBlanc, H., D. Lawrence, E. Varfrolomeev, K. Totpal, J. Morlan, P. Schow, S. Fong, R. Schwall, D. Sinicropi, and A. Ashkenazi. 2002. Tumor-cell resistance to death receptor- induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8, 274-281. DOI ScienceOn |
29 | Lee, J., J. S. Shin, J. Y. Park, D. Kwon, S. J. Choi, S. J. Kim, and I. H. Choi. 2003. p38 mitogen-activated protein kinase modulates expression of tumor necrosis factor-related apoptosis- inducing ligand induced by interferon-gamma in fetal brain astrocytes. J. Neurosci. Res. 74, 884-890. DOI ScienceOn |
30 | Gonzalez-Guerrico, A. M. and M. G. Kazanietz. 2005. Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase C delta. J. Biol. Chem. 280, 38982-38991. DOI |
31 | Guicciardi, M. E., S. F. Bronk, N. W. Werneburg, and G. J. Gores. 2007. cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. Am. J. Physiol. Gastrointest Liver Physiol. 292, 1337-1346. DOI |
32 | Hao, C., J. H. Song, B. His, J. Lewis, D. K. Song, K. C. Petruk, D. L. Tyrrell, and N. M. Kneteman. 2004. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 64, 8502-8506. DOI ScienceOn |
33 | Choi, Y. H., W. H. Lee, K. Y. Park, and L. Zhang. 2000. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn. J. Cancer Res. 91, 164-173. DOI |
34 | Ashkenazi, A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R. H. Schwall. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162. DOI ScienceOn |
35 | Chawla-Sarker, M., S. I. Bae, F. J. Reu, B. S. Jacobs, D. J. Lindner, and E. C. Borden. 2004. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11, 915-923. DOI ScienceOn |
36 | Choi, K., S. Song, and C. Choi. 2008. Requirement of caspases and p38 MAPK for TRAIL-mediated ICAM-1 expression by human astroglial cells. Immunol. Lett. 117, 168-173. DOI ScienceOn |
37 | Choi, Y. H., L. Zhang, W. H. Lee, and K. Y. Park. 1998. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int. J. Oncol. 13, 391-396. |
38 | Cohen, J. H., A. R. Kristal, and J. L. Stanford. 2000. Fruit and vegetable intakes and prostate cancer risk. J. Natl. Cancer Inst. 5, 61-68. |
39 | Conklin, C. M., J. F. Bechberger, D. McFabe, N. Guthrie, E. M. Kurowska, and C. C. Naus. 2007. Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells. Carcinogenesis 28, 93-100. DOI ScienceOn |